Buszek Samantha M, Roy-Chaudhury Prabir, Yadlapalli Ganesh
University of Cincinnati College of Medicine, Cincinnati, OH.
Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.
ACG Case Rep J. 2016 Aug 17;3(4):e104. doi: 10.14309/crj.2016.77. eCollection 2016 Aug.
Olanzapine is an atypical antipsychotic agent that was approved by the Food and Drug Administration in 1996 for treatment of psychotic disorders, bipolar disorder, and schizophrenia. Since that time, numerous case reports have been published that describe the association of olanzapine and the development of pancreatitis. Furthermore, 3 reports suggest the mechanism of olanzapine-induced hypertriglyceridemia as the etiology of this progression. We report a case of a 36-year-old man who developed necrotizing pancreatitis secondary to olanzapine-induced hypertriglyceridemia. This case, to our knowledge, is the most severe case of this progression and the first case requiring plasmapheresis for acute management.
奥氮平是一种非典型抗精神病药物,于1996年被美国食品药品监督管理局批准用于治疗精神障碍、双相情感障碍和精神分裂症。自那时以来,已发表了大量病例报告,描述了奥氮平与胰腺炎发生之间的关联。此外,有3份报告提出奥氮平诱导的高甘油三酯血症是这一病程的病因机制。我们报告一例36岁男性,其因奥氮平诱导的高甘油三酯血症继发坏死性胰腺炎。据我们所知,该病例是这一病程最严重的病例,也是首例需要进行血浆置换进行急性治疗的病例。